CVRx (NASDAQ:CVRX – Get Free Report) had its price target cut by research analysts at Cantor Fitzgerald to $2.00 in a note issued to investors on Friday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Cantor Fitzgerald‘s price target would suggest a potential upside of 229.27% from the stock’s current price.
CVRX has been the subject of a number of other reports. Craig Hallum downgraded shares of CVRx from a “buy” rating to a “hold” rating and set a $4.00 price target for the company. in a report on Friday, August 7th. Wall Street Zen lowered shares of CVRx from a “sell” rating to a “strong sell” rating in a research report on Sunday. Lake Street Capital reduced their price objective on shares of CVRx from $3.50 to $1.50 and set a “hold” rating on the stock in a research note on Friday, November 6th. Weiss Ratings restated a “sell (e+)” rating on shares of CVRx in a research report on Friday, October 30th. Finally, Piper Sandler cut shares of CVRx from an “overweight” rating to a “neutral” rating and set a $4.00 target price for the company. in a research note on Friday, August 7th. One analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $2.70.
Get Our Latest Analysis on CVRX
CVRx Stock Performance
Shares of CVRX opened at $0.61 on Friday. The company has a current ratio of 6.80, a quick ratio of 5.71 and a debt-to-equity ratio of 4.24. The stock has a market cap of $17.30 million, a P/E ratio of -0.30 and a beta of 0.81. The company has a 50-day moving average of $1.85 and a two-hundred day moving average of $5.00. CVRx has a 12-month low of $0.60 and a 12-month high of $10.28.
CVRx (NASDAQ:CVRX – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.02). The company had revenue of $13.83 million during the quarter, compared to analysts’ expectations of $13.93 million. CVRx had a negative net margin of 88.28% and a negative return on equity of 208.45%. As a group, research analysts predict that CVRx will post -2.04 EPS for the current fiscal year.
Institutional Investors Weigh In On CVRx
Institutional investors have recently bought and sold shares of the stock. Deutsche Bank AG acquired a new position in CVRx during the second quarter worth approximately $62,000. Renaissance Technologies LLC purchased a new position in CVRx during the first quarter worth approximately $183,000. Bank of America Corp DE purchased a new position in CVRx during the second quarter worth approximately $102,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of CVRx in the 2nd quarter valued at $107,000. Finally, Empowered Funds LLC acquired a new position in shares of CVRx in the 3rd quarter valued at $63,000. 75.27% of the stock is currently owned by hedge funds and other institutional investors.
CVRx Company Profile
CVRx, Inc. is a medical technology company that develops and commercializes implantable neuromodulation devices for cardiovascular conditions. Its technology is designed to influence the autonomic nervous system, which helps regulate functions such as heart rate and blood pressure. The company’s primary product is Barostim, an implantable system that delivers electrical signals to baroreceptors in the carotid artery. In the United States, Barostim is approved to improve symptoms for certain patients with heart failure who remain symptomatic despite medical therapy.
See Also
- Five stocks we like better than CVRx
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Receive News & Ratings for CVRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVRx and related companies with MarketBeat.com's FREE daily email newsletter.
